OptiScan Biomedical Corporation has developed an innovative monitoring platform for use in hospital intensive care units (ICU) to support clinicians in detecting changes more rapidly in critically ill patients, enabling more timely intervention. The OptiScanner® platform is presently focused on delivering automated bedside glucose monitoring to support clinicians’ reach and maintain a user-defined target glucose range.

The company’s lead product, the OptiScanner 5000, is a first-of-its-kind automated, bedside glucose monitoring system that measures values directly from plasma using spectroscopy technology without the need for calibration.

The system prominently displays glucose level trend data with updates every 15 minutes to help manage patients’ glucose levels within a target range.

To meet the complex monitoring needs of critically ill patients, OptiScan Biomedical is expanding the capabilities of the OptiScanner platform technology to detect additional metabolic and hemodynamic analytes within the same blood sample, which will provide valuable trending data about the condition of a critically ill patient.

OptiScan Biomedical has received CE Mark certification for the OptiScanner 5000 system. The company completed a pivotal, multi-center Investigational Device Exemption (IDE) clinical study and preliminary results were presented at AAST 2016. Learn more.

CAUTION: In the U.S., the OptiScanner system is an investigational device limited by Federal (U.S.) law to investigational use. This investigational product has not been cleared or approved by the U.S. Food and Drug Administration for marketing in the United States.
OptiScan Biomedical has received CE Mark certification for the OptiScanner 5000 system.